DMRA
Damora Therapeutics, Inc.NASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$1.56B
P/E Ratio
—
EPS
$-3.98
Beta
1.60
52W High
$38.33
52W Low
$2.35
50-Day MA
$26.26
200-Day MA
$15.44
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Damora Therapeutics, Inc.
Damora Therapeutics, Inc., a clinical-stage biotechnology company, develops molecule therapeutics for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company is headquartered in Copenhagen, Denmark.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-36.54M |
| Operating Margin | 0.00% |
| Return on Equity | -163.80% |
| Return on Assets | -16.50% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $-110.11 |
| Price-to-Book | 163.79 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | 0.46 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $60.30M |
| Float | $47.60M |
| % Insiders | 1.46% |
| % Institutions | 8.12% |
Historical Volatility
HV 10-Day
62.05%
HV 20-Day
99.86%
HV 30-Day
87.63%
HV 60-Day
112.51%
HV Rank
—
Volatility is currently contracting
Analyst Ratings
Consensus ($46.20 target)
4
BuyData last updated: 4/14/2026